Loading clinical trials...
Loading clinical trials...
A Phase I/IIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus
Conditions
Interventions
OPF-310
Locations
1
United States
University of Illinois Hospital & Health Sciences System
Chicago, Illinois, United States
Start Date
June 10, 2025
Primary Completion Date
June 30, 2027
Completion Date
June 30, 2027
Last Updated
March 2, 2026
NCT06807190
NCT03970720
NCT04786262
NCT06748963
NCT06329375
NCT06945406
For participant-focused inquiries, please contact:
CONTACT
847-500-9204opf-310_autoreply@opf-america.comFor physician or professional inquiries, please contact:
CONTACT
847-200-6731opf-310_project_team@opf-america.comLead Sponsor
Otsuka Pharmaceutical Factory, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions